论文部分内容阅读
目的:探讨口服麦冬多糖MDG-1后在胃肠道内的变化。方法:采用异硫氰酸荧光素(FITC)对麦冬多糖MDG-1进行标记,测定取代度。采用荧光凝胶色谱法(HPGPC)对消化道内含量进行测定。胃内含量变化测定:SD雄性大鼠随机分成6组,其中5组分别口服给予不同剂量F-MDG-1,空白组给予水,在1 h时测定含量;另取SD雄性大鼠随机分成6组,其中5组分别经口给予相同剂量F-MDG-1,空白组给予水,分别在0,1,2,4 h时测定含量。小肠道内含量测定:SD-雄性大鼠分成4组,空白组1组及给药组3组,经胃幽门部注射给药后立即分别结扎胃幽门部及小肠末端,空白组给予水适量,给药组给予F-MDG-1溶液适量,分别在1,2,4 h测定内容物内F-MDG-1含量。大肠内含量测定:SD-雄性大鼠分成4组,空白组1组及给药组3组,每组6只,给药方法:经小肠末端部注射给药后立即分别结扎小肠末端及大肠末端近肛门部。空白组给予水适量,给药组给予F-MDG-1溶液适量,分别在1,2,4 h测定大肠内容物内F-MDG-1含量。结果:给予相同剂量的F-MDG-1,随着药物在胃内驻留时间的延长,其浓度下降。而在给予不同浓度F-MDG-1后,在1 h时测得浓度占给药量的百分比随着给药剂量的增加而增加;但将pH调7.2后,其含量未变化。分别单次给予小肠、大肠F-MDG-1后,随着药物在肠道内驻留时间的延长,其含量逐渐降低。结论:采用FITC对MDG-1进行标记,并采用荧光色谱法对MDG-1在胃肠道内含量变化进行研究是可行的。MDG-1在胃内不分解,其主要代谢部位在肠道,其原因可能是肠道内环境及细菌共同作用的结果。
Objective: To investigate the changes of gastrointestinal tract after Oral Radix Ophiopogonis MDG-1. Methods: Ophiopogon japonicus polysaccharide MDG-1 was labeled with fluorescein isothiocyanate (FITC) to determine the degree of substitution. The content of digestive tract was determined by fluorescence gel chromatography (HPGPC). The contents of gastric contents in SD rats were randomly divided into 6 groups, of which 5 groups were orally administered with different doses of F-MDG-1, while those in the blank group were given water and measured at 1 h. SD male rats were randomly divided into 6 groups Group, in which 5 groups were orally administered the same dose of F-MDG-1, the blank group given water, respectively, at 0,1,2,4 h determination of content. Small intestine content determination: SD-male rats were divided into 4 groups, the blank group 1 and the administration group 3 group, after gastric pylorus injection immediately after the administration of stomach pylorus and end of the small intestine, the blank group to give appropriate amount of water to The medicine group was given the appropriate amount of F-MDG-1 solution, and the contents of F-MDG-1 in the contents were measured at 1, 2 and 4 hours respectively. Large intestine content determination: SD-male rats were divided into 4 groups, the blank group 1 group and the administration group 3 groups of 6, each group administration method: the end of the small intestine immediately after administration of the end of the small intestine and large intestine Near the anus department. The amount of F-MDG-1 solution was given to the blank group and the F-MDG-1 solution was given to the medication group. The content of F-MDG-1 in the contents of the large intestine was measured at 1, 2 and 4 hours respectively. Results: The same dose of F-MDG-1 was administered, and the concentration of F-MDG-1 decreased with the residence time of the drug in the stomach. However, after administration of different concentrations of F-MDG-1, the percentage of the dose at 1 h was increased with the dose of F-MDG-1 at 1 h. However, the content of F-MDG-1 did not change after adjusting the pH to 7.2. After a single administration of small intestine and large intestine F-MDG-1, with the drug in the intestine residence time extension, the content gradually decreased. Conclusion: It is feasible to use FITC to mark MDG-1 and to study the content of MDG-1 in gastrointestinal tract by fluorescence chromatography. MDG-1 does not decompose in the stomach, its main metabolic site in the intestine, the reason may be the intestinal environment and bacterial interactions.